

Phase IV Study of Cladribine Tablets and Quality of Life: CLARIFY-MS

Schippling¹, D. Langdon², A. Solari³, B. Brochet^{4,5}, R. Hupperts⁶, F. Piehl⁷, J. Lechner-Scott⁸, X. Montalban^{9,10}, B. Keller¹¹, N. Alexandri¹¹

¹University Hospital Zürich, Rämistrasse, Zürich, Switzerland; ²Royal Holloway, University of London, Egham, Surrey, UK; ³Foundation IRCCS Neurological Institute C. Besta, Milano, Italy; ⁴Université Bordeaux-Segalen, France; ⁵Centre Hospitalier-Universitaire of Bordeaux, France; ⁶Orbis Medisch Centrum, Sittard, The Netherlands; ⁷Karolinska Institutet, Stockholm, Sweden; ⁸University of Newcastle, University Drive, Callaghan, Australia; ⁹Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada; ¹⁰Department of Neurology-Neuroimmunology, Multiple Sclerosis of Catalonia (Cemcat), Vall d'Hebron University Hospital, Vall d'Hebron, Barcelona, Spain; ¹¹Merck KGaA, Darmstadt, Germany

Disclosure Statement

The trial is sponsored by Merck KGaA, Darmstadt, Germany.

Author Disclosure Statement

SS has been a steering committee member of clinical trials and has received travel support and speaker fees from Almirall, Bayer, Biogen, Sanofi, Merck, Novartis, and TEVA. **DL** has participated in speaker bureau for Bayer, Merck, Almirall, TEVA, Roche, Novartis, Biogen, Sanofi; has had consultancy from Novartis, Bayer, Merck, Biogen, TEVA; has had research grants from Bayer, Merck, Novartis, Biogen. All are paid into DL's university. **AS** has served as on the advisory boards for Genzyme-Sanofi, Merck and Novartis and has been invited to speak on behalf of Almirall, Biogen Idec, Excemed, Merck-Serono and TEVA. **BB** has received consultancy fees, speaker fees, research grants (non-personal), or honoraria from Novartis, Biogen-Idec, Merck, Bayer Schering, Roche, Medday, Bayer, Actelion, Teva and Genzyme Sanofi. **RH** has received institutional research grants and fees for lectures and advisory boards from Biogen, Merck, and Genzyme Sanofi. **FP** has received unrestricted academic research grants from Biogen, Genzyme and Novartis, and on his behalf, his Department has received travel support and/or compensation for lectures from Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva, which have been exclusively used for the support of research activities. **JL-S** has accepted travel compensation from Novartis, Biogen and Merck Serono. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Bayer Health Care, Biogen, Sanofi-Genzyme, Merck, Novartis and Teva. **XM** has been a steering committee member of clinical trials or participated in advisory boards of clinical trials with Actelion, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon, Roche, Sanofi-Genzyme and Teva Pharmaceutical. **BK** is an employee of Merck KGaA, Darmstadt, Germany. **NA** is an employee of Merck KGaA, Darmstadt, Germany.